30.04.2018 14:30:00

PTC Therapeutics to Participate at Upcoming Investor Conference

SOUTH PLAINFIELD, N.J., April 30, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health Care Conference, on Tuesday, May 15th at 2:20 p.m. PT

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. PTC's current Investor Presentation are available at the same website location.

About PTC Therapeutics, Inc.
PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Founded 20 years ago, PTC Therapeutics has successfully launched two rare disorder products and has a global commercial footprint. This success is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

FOR MORE INFORMATION PLEASE CONTACT:


Media:

Investors:

Jane Baj

Emily Hill

+1 (908) 912-9167

+1 (908) 912-9327

jbaj@ptcbio.com

ehill@ptcbio.com

Cision View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conference-300638566.html

SOURCE PTC Therapeutics, Inc.

Analysen zu PTC Therapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

PTC Therapeutics Inc 41,00 0,00% PTC Therapeutics Inc